Pfizer (NY:PFE)

The Implementation Pivot: How Accenture Defied the ‘SaaS-pocalypse’ with a Massive AI Rebound

Today 14:21 EST

As of February 27, 2026, the global technology sector is grappling with a profound identity crisis often dubbed the "SaaS-pocalypse." While many software-as-a-service providers have seen their...

Industrial Renaissance: Sector Surges 27% in Q4 2025 as Healthcare and Consumer Discretionary Lag

Topics Artificial Intelligence Economy

Today 14:18 EST

The fourth-quarter 2025 earnings season has delivered a definitive verdict on the health of the American economy: the "Industrial Renaissance" is no longer a forecast, but a realized phenomenon. While...

As of late February 2026, the financial narrative of the past two years has been dominated by a singular force in the healthcare sector: Eli Lilly & Company (NYSE: LLY). Once considered a traditional...

Topics Artificial Intelligence Economy

The Lilly Era: How Eli Lilly Transformed into a Trillion-Dollar Healthcare Titan

Today 11:55 EST

Though Bristol-Myers Squibb has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Topics Artificial Intelligence ETFs

Is Bristol-Myers Squibb Stock Underperforming the Nasdaq?

Today 11:16 EST

Via Barchart.com

Topics Stocks

The Great Pivot: Inside Novavax’s 2026 Turnaround and the Road to Combination Vaccines

Today 10:27 EST

As of today, February 27, 2026, the biotech sector is witnessing a dramatic reappraisal of one of its most storied pandemic-era players. Novavax (NASDAQ: NVAX) has surged 17.4% following the release of...

Via Finterra

Topics Economy

PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

Today 10:00 EST

From Pfizer Inc.

Via Business Wire

Amneal (AMRX) Q4 2025 Earnings Call Transcript ↗

Today 9:59 EST

Amneal (AMRX) Q4 2025 Earnings Call Transcript

Novavax Stock Hits Over 1-Year High: Is Sanofi’s Flu-COVID Shot The Post-Pandemic Growth Driver? ↗

Topics Earnings

Today 1:54 EST

Novavax said it is pivoting toward a partnership-led model, including a licensing deal with Pfizer for its Matrix-M technology.

Over the last six months, Zoetis’s shares have sunk to $129.91, producing a disappointing 16.4% loss - a stark contrast to the S&P 500’s 7.2% gain. This may have investors wondering how to approach the...

Topics Earnings

2 Reasons to Like ZTS (and 1 Not So Much)

February 26, 2026

Via StockStory

Topics Stocks

OPKO Health (OPK) Q4 2025 Earnings Call Transcript ↗

February 26, 2026

OPKO Health (OPK) Q4 2025 Earnings Call Transcript

Even amid volatility, Pfizer keeps rewarding shareholders year after year.

Topics Earnings

Love Dividends? 1 Stock to Buy Now With a Yield Over 6%.

February 26, 2026

Via Barchart.com

Topics Artificial Intelligence

Pfizer Secures Full FDA Approval for BRAFTOVI in First-Line Colorectal Cancer, Bolstering Oncology Growth Strategy

February 26, 2026

In a move that solidifies a new standard of care for a high-risk patient population, the U.S. Food and Drug Administration (FDA) has granted full approval to Pfizer Inc. (NYSE: PFE) for its BRAFTOVI...

The Pivot to Growth: Viatris (VTRS) Enters Phase 2 with 2026 Dividend and Capital Allocation Strategy

Topics Economy Intellectual Property

February 26, 2026

As of February 26, 2026, Viatris Inc. (NASDAQ: VTRS) finds itself at a defining crossroads. For years, the company was viewed by many on Wall Street as a "value trap"—a debt-laden giant formed from the...

Via Finterra

Topics Economy

This Pfizer Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday ↗

February 26, 2026

Via Benzinga

Viatris (NASDAQ:VTRS) Posts Better-Than-Expected Sales In Q4 CY2025

February 26, 2026

Medication company Viatris (NASDAQ:VTRS) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 5% year on year to $3.7 billion. The company’s full-year revenue guidance of...

Via StockStory

NVAX Stock Rises Overnight Ahead Of Q4 Print With Pfizer Tailwinds — Analyst Warns Of 20% Crash ↗

February 26, 2026

Koyfin analysts expect revenue to grow nearly 28% from the last quarter and forecast losses to narrow significantly.

Gilead’s Twice-Yearly HIV Breakthrough: A Paradigm Shift in Global Prevention and Market Dominance

February 25, 2026

The global landscape of HIV prevention and treatment has reached a historic turning point following the clinical triumph and subsequent commercial launch of Gilead Sciences’ (Nasdaq: GILD) lenacapavir,...

Eli Lilly Just Took 2 Major Steps Forward in the Billion-Dollar Obesity Drug Market. Here's What You Need to Know. ↗

Topics Intellectual Property

February 25, 2026

Eli Lilly has seen revenue and earnings soar in recent years.

Pfizer stock rises after FDA fully approves Braftovi combo for metastatic colorectal cancer with BRAF V600E mutation.

Pfizer's Braftovi Regimen Wins Complete FDA Nod For Colorectal Cancer Treatment ↗

February 25, 2026

Via Benzinga

Novo Nordisk's 40% Fall May Be Creating A Deep-Value Moment ↗

February 25, 2026

Novo Nordisk now trades at just 10.6x earnings after a 58% crash, far below Eli Lilly, Vertex, and Pfizer — signaling a valuation reset.

Via Benzinga

Pfizer Stock: Is PFE Underperforming the Healthcare Sector?

February 25, 2026

Due to Pfizer’s underperformance relative to the healthcare sector over the past year, Wall Street analysts remain cautious about the stock’s prospects

Via Barchart.com

Topics ETFs Intellectual Property World Trade

U.S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer

February 24, 2026

From Pfizer Inc.

Via Business Wire

Novavax Q4 Earnings Preview: Wall Street Expects Wider Losses Amid Diversification Efforts ↗

February 24, 2026

According to data from Fiscal AI, Novavax is expected to report a quarterly loss per share of $0.55, higher than the loss of $0.52 reported in the corresponding quarter of 2024.

This Dividend Giant Pfizer Could Turn a Boring Healthcare Allocation Into Serious Income ↗

Topics Artificial Intelligence Earnings

February 24, 2026

Pfizer says it is standing behind its dividend, which makes the stock's 6.4% yield quite attractive.

TinyGemsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Dr. Freda Lewis-Hall to Board and Scientific Advisory Committee Chair

Topics Intellectual Property

February 24, 2026

Via Investor Brand Network

Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity

February 24, 2026

EQNX::TICKER_START (NASDAQ:HELP),(CBOE:HELP),(NYSE:TAK),(NASDAQ:CMPS),(NYSE:PFE),(NYSE:BMY) EQNX::TICKER_END

Via FinancialNewsMedia

Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee

February 24, 2026

In this role, Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and translational rigor across Helus’ novel serotonergic agonist (“NSA”) portfolio This news release...

Via FinancialNewsMedia

Nasdaq, S&P 500 Futures Steady After AI Fears Roil Tech: Why IBM, NVDA, NFLX, HIMS, PFE Are On Traders' Radar Today ↗

February 24, 2026

Data from Stocktwits indicated retail sentiment on SPY and QQQ remained ‘bearish’ on Stocktwits.

Novo Nordisk Shares Tumble 15.1% After CagriSema Fails to Topple Eli Lilly in Head-to-Head Trial

Topics Artificial Intelligence ETFs Government

February 23, 2026

The undisputed reign of Novo Nordisk in the weight-loss drug sector faced its most severe challenge to date on February 23, 2026, as the company’s US-traded shares (NYSE: NVO) plummeted 15.1% in a...